Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes Mellitus

PHASE3CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 20, 2021

Primary Completion Date

April 20, 2021

Study Completion Date

May 10, 2021

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Liraglutide

Liraglutide is a glucagon-like peptide type 1 (GLP-1) analogue. We had fond its cognitive improvement effects in an observational study. In order to confirm the effects, the investigators conduct a randomized, controlled study.

DRUG

Oral antidiabetic drugs: Metformin, Sulfonylureas (2nd generation), Thiazolidinediones, α-Glucosidase inhibitors, and Glinides

oral antidiabetic drugs (OADs) or insulin, except for glucagon-like peptide type 1 (GLP-1) analogues

Trial Locations (1)

400042

The third hospital affiliated to the Third Military Medical University, Chongqing

All Listed Sponsors
lead

Third Military Medical University

OTHER

NCT05360147 - Liraglutide Improve Cognitive Function in Patients With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter